Elekta

Sweden - StockholmBiotechnology1 H-1B visas (FY2023)

Focus: Elekta is a Swedish medical technology company specializing in radiation therapy and oncology treatment solutions. The company operates at the intersection of hardware, software, and clinical innovation in cancer care.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Elekta

AI assessmentNot Hiring

No open roles listed right now. Follow Elekta to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

15 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Pre-operative Stereotactic Radiosurgery

Brain Metastases, Adult

N/A

Clinical Trials (1)

NCT05341739A Phase II Study of Pre-Op SRS Followed by Surgical Resection for Brain Metastases

N/A

Help build intelligence for Elekta

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep focus on oncology with 15 active pipeline programs spanning multiple radiotherapy modalities and indications
European headquarters with global reach provides exposure to diverse regulatory environments and healthcare systems
Technology-driven approach combining imaging (MRI, ultrasound) with precision radiotherapy attracts engineers and clinical innovators

Watch Out For

Currently zero active job openings signals contraction or hiring freeze, limiting near-term opportunities
Mixed H1B sponsorship record (1 approval, 1 denial in 2023) suggests inconsistent immigration support capacity

Generated by Claude from Elekta's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

mask for immobilization

Spinal Metastases

N/A

Clinical Trials (1)

NCT05155423A Prospective Study of Performing MRI Simulation in Treatment Position in Spinal Stereotactic Body Radiation Therapy

N/A

radiotherapy

Tumors at All Sites Which Will Receive Radiotherapy

N/A

Clinical Trials (1)

NCT04351204The MR-Linac Technical Feasibility Protocol

N/A

MRI scan

Lung Cancer

N/A

Clinical Trials (1)

NCT03048760Magnetic Resonance Imaging (MRI) for the Delineation of Organs At Risk (OAR) and Target Volumes in Lung Cancer Patients

N/A

Transperineal Ultrasound

Prostate Cancer

N/A

Clinical Trials (1)

NCT01545154The Use of Transperineal Ultrasound for Radiation Therapy Treatment Planning and Image Guidance in the Treatment of Prostate Cancer

N/A

Prostate radical radiotherapy

Prostate Cancer

N/A

Clinical Trials (1)

NCT06638541Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions

N/A

Radiation therapy

Oncology

N/A

Clinical Trials (1)

NCT04075305The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

N/A

uniform dose radiotherapy

Prostate Cancer (Adenocarcinoma)

N/A

Clinical Trials (1)

NCT07391982Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions

N/A

Low dose radiotherapy A

Gonarthrosis

N/A

Clinical Trials (1)

NCT04424628Radiotherapy 3 vs 6 Gy in Gonarthrosis and Coxarthrosis

N/A

Personalized Ultra-fractionated stereotactic ablative radiotherapy

Cancer, Lung

Phase 1

Clinical Trials (1)

NCT06712745Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung

Phase 1

Accelerated Partial Breast Irradiation

Ductal Breast Carcinoma In Situ

Phase 2

Clinical Trials (1)

NCT02526498Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery

Phase 2

MR Guided Single Fraction Stereotactic Body Radiation Therapy

Colorectal Cancer

Phase 2

Clinical Trials (1)

NCT06130280A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer

Phase 2

Endo-HDR

Rectal Cancer

Phase 2

Clinical Trials (1)

NCT02017704Chemoradiation or Brachytherapy for Rectal Cancer

Phase 2

Ultra-fractionated radiation therapy

Stage IV Cervical Cancer FIGO 2018

Phase 2

Clinical Trials (1)

NCT05021237Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy for Metastatic Cervical Cancer

Phase 2

Gardasil 9

Cervical Cancer

Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 14 clinical trials

Top TAs: Oncology

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

13 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

50%

Rate

Source: USCIS H-1B Employer Data Hub